Enterprise Value
433.3M
Cash
323.5M
Avg Qtr Burn
N/A
Short % of Float
16.26%
Insider Ownership
13.64%
Institutional Own.
84.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARCT-154 Details COVID-19 | Phase 3 Update | |
ARCT-810 Details Ornithine transcarbmylase deficiency, Urea cycle disorder | Phase 2 Data readout | |
ARCT-032 Details Cystic fibrosis, Lung disease | Phase 1b Initiation | |
ARCT-021 Details COVID-19 | Failed Discontinued |